Innovation Pharmaceuticals (QB) Stock Price

-0.0078 (-15.98%)
Volume 6,071,887
Bid Price 0.04
Ask Price 0.042
News -
Day High 0.0649


52 Week Range


Day Low 0.039
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Innovation Pharmaceuticals Inc (QB) IPIX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0078 -15.98% 0.041 16:59:00
Open Price Low Price High Price Close Price Prev Close
0.04885 0.039 0.0649 0.041 0.0488
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
442 6,071,887 $ 0.044441 $ 269,842 - 0.0192 - 0.54
Last Trade Time Type Quantity Stock Price Currency
15:54:02 20,000 $ 0.041 USD


Draw Mode:

Innovation Pharmaceuticals Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 20.02M 488.23M 342.36M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
486.61k $ - - - -

more financials information »

Innovation Pharmaceuticals (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IPIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0430.06490.03580.045001437,669-0.002-4.65%
1 Month0.0420.06490.03580.0424589821,482-0.001-2.38%
3 Months0.02910.06490.01920.0362484702,9800.011940.89%
6 Months0.0440.06490.01920.0359332674,546-0.003-6.82%
1 Year0.30190.540.01920.12320961,799,996-0.2609-86.42%
3 Years0.1620.650.01920.19731631,800,199-0.121-74.69%
5 Years0.78251.170.01920.21131091,234,940-0.7415-94.76%

Innovation Pharmaceuticals (QB) Description

An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now